SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Crispin, J C
Right arrow Articles by Alarcón-Segovia, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crispin, J C
Right arrow Articles by Alarcón-Segovia, D
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission

J C Crispin

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, México DF, Mexico City, Mexico

J Alcocer-Varela

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, México DF, Mexico City, Mexico, jalcocee{at}sni.conacyt.mx

P de Pablo

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, México DF, Mexico City, Mexico

A Martínez

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, México DF, Mexico City, Mexico

Y Richaud-Patin

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, México DF, Mexico City, Mexico

D Alarcón-Segovia

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, México DF, Mexico City, Mexico

Little is known about the immune system of patients with systemic lupus erythematosus(SLE) during periods of silent disease. To address this issue we analysed lymphoid populations and cytokine productionof mononuclearcells obtained from SLE patients in remission.We studied 43 patients with inactive disease, 10 with active disease and 30 controls. Remission was defined as at least 1 year during which lack of clinical disease activity permitted withdrawal of all treatment. Remission length ranged from 1 to 30 years. Flow cytometry and ELISA were used to study lymphoid populations (CD4, CD8 and CD19) and cytokineproduction(IL-2, 4, 10, 12 and 18). Patientswith short remission periods (up to 15 years) exhibited an increased percentage of B cells; production of IL-2, IL-10 and IL-12 was decreased;productionof IL-18 was increased. Interestingly, patients from groups with long time of inactive disease had corrected most alterations, but had an impaired IL-18 expression. IL-12 production correlated strongly with the length of the remission period (r 0.7565). The immune system of patients with inactive lupus has partially corrected the disturbances present during disease activity.This is accomplishedgradually, sometimes until counter-regulatoryalterationsare developed. This may allow patients to remain without disease activity.

Key Words: autoimmunity • cytokines • disease activity • immunoregulation • SLE

Lupus, Vol. 12, No. 5, 386-393 (2003)
DOI: 10.1191/0961203303lu368oa
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement